An observational study in Peripheral or Central Neuropathic Pain, sponsored by HK inno.N Corporation. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by HK inno.N Corporation · Observational
Among 38 studies in Neuralgia with a site in Korea, Republic of — 2 open to participants now, 2 under way, none of them phase 3. Neuralgia · Korea, Republic of.
Among the 38 studies in Neuralgia with a site in Korea, Republic of, this one is the only one that started in 2025, is one of 4 observational ones, and was the 38th registered.
1,101 studies on the registry are indexed under Neuralgia; 242 are open to participants now.
Browse Neuralgia studies →2 of the 38 studies in Neuralgia with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Jeeyoun Moon · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,217 is above the median of 102 across 232 observational studies indexed under Neuralgia.
Median enrollment 90 across the 34 interventional studies, 456 across the 4 observational. Of the 25 that completed or were terminated, 7 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 38 have an industry lead sponsor. The 10 most frequent:
HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.
HK inno.N Corporation has 1 study filed under Neuralgia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 38 studies in Neuralgia with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to assess the proportion of patients with peripheral or central neuropathic pain who achieve at least a 50% improvement in pain at Week 12 after receiving Kabalin Cap.(Pregabalin). The study will also evaluate changes in pain characteristics, severity, and intensity; improvement in pain-related sleep interference; and safety information collected during the study period.
This study will evaluate pain-related outcomes and safety in patients with peripheral or central neuropathic pain who receive Kabalin Cap.(Pregabalin). At Week 12 after treatment initiation, the proportion of patients who achieve at least a 50% improvement in pain will be assessed. Changes in pain characteristics, severity, and intensity will also be evaluated. In addition, the study will assess improvement in pain-related sleep interference and collect safety information observed during the study period.
University-affiliated hospitals and general hospitals where the study drug is administered
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Proportion of participants with a ≥50% improvement in pain severity from baseline at Week 12
The proportion of participants whose pain severity score, as assessed using the SF-MPQ, shows a ≥50% improvement from baseline after 12 weeks of treatment with Kabalin Cap. will be reported
Time frame: At Week 12 after enrollment
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Jun 2028, 40 months after the start.
Of 88 observational studies under Neuralgia, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 40 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.